Choong ANG Vaccine Laboratory

At a glance

Choong ANG Vaccine Laboratory filed 28 disclosures in the last 12 months, including 4 insider, 3 earnings, 2 buyback, 1 contract and 1 5% holder. The most recent key filing was on Aug 6.

Revenue for 2025 was ₩49.1B, up 7.6% on 2024. Operating margin was 13.2% against 12.6% a year earlier. Debt was 17% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩24.5B and operating profit of ₩4.1B.

The 2025 annual report lists 194 employees with an average tenure of 9.7 years and average pay of ₩57.1M, #1111 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩170M each on average. It paid ₩200 per common share in cash dividends, against ₩170 a year earlier (+17.6%). 윤인중 and related parties held 34.99% at year end.

From the 2025 annual report

Staff: 194 (126 men, 68 women), of whom 16 on fixed-term contracts. Total pay for the year: ₩11B. Directors and auditors: 7, paid ₩1.2B in total.

Dividends (common shares)

Largest shareholder

윤인중 holds 24.32%; with 11 related parties the group holds 34.99% of common shares at year end (from 34.50% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary